Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma

被引：33
|
作者：
Kindler, HL [1 ]
机构：
[1] Univ Chicago, Med Ctr, Dept Hematol Oncol, Chicago, IL 60637 USA
来源：
LUNG CANCER | 2004年 / 45卷
关键词：
novel cytostatic agents; vascular endothetial; growth factor; epidermal growth factor; platelet derived growth factor; tyrosine kinase;
D O I：
10.1016/j.lungcan.2004.04.022
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
It is now known that vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are autocrine growth factors in malignant mesothelioma; epidermal growth factor receptor (EGFR) is also highly overexpressed. Cytotoxic drugs that target these growth factors offer fresh potential for the treatment of mesothelioma. Clinical trials have recently been initiated to evaluate the anti-tumour activity of the VEGF inhibitors SU5416, bevacizumab and thalidomide. ZD1839 (Iressa, AstraZeneca), an inhibitor of EGFR tyrosine kinase, is also being evaluated. Two clinical trials are planned to evaluate the two PDGF inhibitors Gleevec (Imatinib mesylate, STI-571, Novartis Pharmaceuticals) and PTK787 (Novartis Pharmaceuticals). (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：S125 / S127
页数：3
相关论文
共 50 条
  • [31] Malignant pleural mesothelioma: beyond the mathematical models
    Leuzzi, Giovanni
    Duranti, Leonardo
    Lococo, Filippo
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S892 - S894
  • [32] Chemotherapy and targeted therapies for unresectable malignant mesothelioma
    Kelly, Ronan Joseph
    Sharon, Elad
    Hassan, Raffit
    LUNG CANCER, 2011, 73 (03) : 256 - 263
  • [33] Historical perspective of the chemotherapy in malignant pleural mesothelioma
    Rivera-Rivera, S.
    Martinez-Prieto, M.
    Flores-de-la-Torre, C. B.
    GACETA MEXICANA DE ONCOLOGIA, 2009, 8 (01): : 33 - 36
  • [34] Malignant pleural mesothelioma: maintenance chemotherapy with pemetrexed
    Nacci, A.
    Rizzo, P.
    Sponziello, F.
    Mazzoni, E.
    Fedele, P.
    Orlando, L.
    Schiavone, P.
    Calvani, N.
    Marino, A.
    Cinieri, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S833 - S833
  • [35] Current chemotherapy strategies in malignant pleural mesothelioma
    de Gooijer, Cornedine Jannette
    Baas, Paul
    Burgers, Jacobus Adrianus
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 (05) : 574 - 583
  • [36] Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy
    Geerinckx, Barbara
    Teuwen, Laure-Anne
    Foo, Tiffany
    Vandamme, Timon
    Smith, Annabel
    Peeters, Marc
    Price, Timothy
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (12) : 1237 - 1249
  • [37] Current concepts in chemotherapy for malignant pleural mesothelioma
    Sorensen, Jens Benn
    CLINICAL RESPIRATORY JOURNAL, 2008, 2 (02): : 74 - 79
  • [38] Concurrent radiotherapy and chemotherapy schedule in malignant mesothelioma
    Smickoska, S
    Jovanovski, D
    Mickovska, V
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 1998, : 689 - 693
  • [39] Systemic chemotherapy in the management of malignant peritoneal mesothelioma
    Garcia-Carbonero, R.
    Paz-Ares, L.
    EJSO, 2006, 32 (06): : 676 - 681
  • [40] REGIONAL CHEMOTHERAPY IN PATIENTS WITH MALIGNANT PERITONEAL MESOTHELIOMA
    Rykov, M.
    Ryabov, A.
    Polyakov, V.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 104 - 104
12345